Axsome Therapeutics, a biopharmaceutical company focused on central nervous system disorders, announced its participation in two upcoming investor conferences in May 2026: the BofA Securities Health Care Conference on May 12 in Las Vegas and the RBC Capital Markets Global Healthcare Conference on May 19 in New York. The company will host fireside chats at both events and provide live webcasts accessible through its website, with replays available for 30 days. These presentations offer investors insights into Axsome's progress and future plans in developing treatments for neurological and psychiatric conditions affecting millions in the U.S.
T3 Defense's stock soared 201% following its subsidiary's expansion of defense technology into industrial materials, signaling strong growth potential. NextCure saw a 20.75% rise driven by a significant short squeeze, reflecting heavy short interest ...
Environics Analytics has named Cenker Ozhelvaci as Head of Sales for its core direct sales teams. Ozhelvaci brings extensive experience from sectors like financial services and technology, having previously led sales at Provenir and Amazon Canada. Hi...
AT&T reported better-than-expected earnings and announced a $10 billion share buyback program. Despite the positive results and buyback plan, the stock still trades at a relatively low valuation of 8 times earnings and offers a 4.6% dividend yield. T...
AstraZeneca reported a 21% increase in core earnings per share to $2.63 for Q2 2026, surpassing analyst expectations of $2.50. Total revenue rose 6% to $15.38 billion, driven by strong sales in oncology and rare disease drugs, offsetting pressure fro...
American Tower Corporation's analyst price targets have dropped from $218.24 to $188 over the past year, reflecting cautious market sentiment. However, the company reported a robust 6.8% revenue growth in Q1 2026, driven by its international towers a...
